Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Constrained Peptide Drugs Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of chronic diseases globally
5.1.1.2. Continuous advancements in peptide chemistry and synthesis techniques
5.1.1.3. Increasing demand for manufacturing of biologics and personalized medicines
5.1.2. Restraints
5.1.2.1. High cost associated with the drug development of peptides
5.1.3. Opportunities
5.1.3.1. Increasing research & development to develop novel constrained peptide drugs
5.1.3.2. Availability of government support for innovative therapies, including constrained peptide drugs
5.1.4. Challenges
5.1.4.1. Issues with low bioavailability of peptides
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Constrained Peptide Drugs Market, by Peptide Type
6.1. Introduction
6.2. Macrocyclic
6.3. Stapled

7. Constrained Peptide Drugs Market, by End-User
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Pharmaceutical Companies

8. Americas Constrained Peptide Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Constrained Peptide Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Constrained Peptide Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Bicycle Therapeutics, Inc.
12.1.2. Biosynth Ltd
12.1.3. IRBM S.p.A.
12.1.4. PeptiDream Co., Ltd.
12.1.5. Pfizer Inc.
12.1.6. Protagonist Therapeutics, Inc.
12.1.7. UCB S.A
12.2. Key Product Portfolio

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing



List of Figures

FIGURE 1. CONSTRAINED PEPTIDE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CONSTRAINED PEPTIDE DRUGS MARKET DYNAMICS
FIGURE 7. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2030 (%)
FIGURE 8. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 10. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CONSTRAINED PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. CONSTRAINED PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. CONSTRAINED PEPTIDE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
TABLE 3. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 6. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY MACROCYCLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STAPLED, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 9. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 12. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 14. ARGENTINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 15. ARGENTINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 16. BRAZIL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 17. BRAZIL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 18. CANADA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 19. CANADA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. MEXICO CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 21. MEXICO CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 25. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 26. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. AUSTRALIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 29. AUSTRALIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. CHINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 31. CHINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. INDIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 33. INDIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. INDONESIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 35. INDONESIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. JAPAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 37. JAPAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. MALAYSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 39. MALAYSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. PHILIPPINES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 41. PHILIPPINES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. SINGAPORE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 43. SINGAPORE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. SOUTH KOREA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 45. SOUTH KOREA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. TAIWAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 47. TAIWAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. THAILAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 49. THAILAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. VIETNAM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 51. VIETNAM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. DENMARK CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 56. DENMARK CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. EGYPT CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 58. EGYPT CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. FINLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 60. FINLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. FRANCE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 62. FRANCE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. GERMANY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 64. GERMANY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. ISRAEL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 66. ISRAEL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. ITALY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 68. ITALY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. NETHERLANDS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 70. NETHERLANDS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. NIGERIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 72. NIGERIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. NORWAY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 74. NORWAY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. POLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 76. POLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. QATAR CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 78. QATAR CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. RUSSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. SAUDI ARABIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. SOUTH AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 84. SOUTH AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. SPAIN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 86. SPAIN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. SWEDEN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 88. SWEDEN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. SWITZERLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 90. SWITZERLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. TURKEY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 92. TURKEY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED ARAB EMIRATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. CONSTRAINED PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 98. CONSTRAINED PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 99. CONSTRAINED PEPTIDE DRUGS MARKET LICENSE & PRICING